Nasdaq
$2.20▼ 0.23%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $156.6MShares out 71.2M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
6- 10.1After-hours26.10.02 06:194Ownership#●●●#●●●
Zentalis Pharmaceuticals, Inc.
Insider Ingmar Bruns of Zentalis Pharmaceuticals reported changes in beneficial ownership of securities as of September 30, 2026. This filing serves as a standard disclosure regarding insider stock transactions.…more
$2.20-0.23%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.19After-hours26.08.20 07:12SCHEDULE 13G/AOwnership
Zentalis Pharmaceuticals, Inc.
Walters Group filed an amended Schedule 13G/A on August 19, 2026, regarding their beneficial ownership in Zentalis Pharmaceuticals, Inc. This filing serves as a mandatory update concerning the investor's stake in the company.…more
$2.20-0.23%vs prev closeView filingShare - 8.19After-hours26.08.20 07:114Ownership
Zentalis Pharmaceuticals, Inc.
Walters Group, William Thurman Walters, and Susan Berkley Walters, who are insiders and major shareholders of Zentalis Pharmaceuticals, filed a Form 4 on August 19, 2026, regarding changes in beneficial ownership as of August 14, 2026. This filing serves as a routine disclosure of changes in the insiders' stock holdings.…more
$2.20-0.23%vs prev closeView filingShare
5 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 1d agoRegular26.10.23 23:15#●●●#●●●
Zentalis Announces Interim Clinical Data for Ovarian Cancer Candidate Azenosertib…more
Zentalis Pharmaceuticals reported interim Phase 1b results showing improved overall survival for patients with Cyclin E1-positive platinum-resistant ovarian cancer treated with azenosertib. These findings are preliminary, and the company continues to advance its registration-intended and Phase 3 confirmatory trials.…more
$2.20-0.23%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 6d agoClosed26.10.19 07:05
●●●●●●●● ●●●●● ●●●●●●
Zentalis Pharmaceuticals reported a median overall survival of 15.8 months for its investigational drug azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer patients. These interim results from the DENALI study support the ongoing Phase 2 and Phase 3 confirmatory trials.…more
$2.20-0.23%vs prev close - 10.1After-hours26.10.02 06:10
●●●●●●●● ●●●●● ●●●●●●
Zentalis Pharmaceuticals has granted stock options for a total of 62,000 shares to three newly hired employees. These grants were issued as an employment inducement under Nasdaq listing rules and have a neutral impact on the company's valuation.…more
$2.20-0.23%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report